In Novo Nordisk A/S v KBP Biosciences Pte Ltd and another and another matter [2025] SGHC(I) 3, the Singapore International Commercial Court granted the ex parte application for a worldwide Mareva injunction in support of a New-York seated arbitration, where it was unlikely the arbitral tribunal or New York courts would grant the injunction sought. Read more: go.gov.sg/2025sghci3.